Novel targets, better treatments
|
|
- Raymond Shepherd
- 6 years ago
- Views:
Transcription
1 Novel targets, better treatments Investor presentation January 2018
2 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline, the slides captioned GLPG: strong investment case GLPG: data rich 2018 Advancing our innovation to market Strong R&D Building an IPF franchise Filgotinib CF portfolio CF approach to a triple combo 2018 late-stage clinical newsflow, statements regarding the development of the triple combination therapy CF program, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials (i) with filgotinib in RA, IBD, and other potential indications (ii) in the CF program, (iii) with GLPG1690, GLPG1205, and GLPG3499 in IPF, (iv) with GLPG1972 in OA, (v) with MOR106 in atopic dermatitis, and expectations regarding the commercial potential of our product candidates. When used in this presentation, the words anticipate, believe, can, could, estimate, expect, intend, is designed to, may, might, will, plan, potential, possible, predict, objective, should, and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements (including that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons), reliance on third parties (including Galapagos collaboration partners AbbVie, Gilead, Servier and MorphoSys) and estimating the commercial potential of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos Securities and Exchange Commission ( SEC ) filing and reports, including Galapagos most recent Form 20-F filing for the year ended December 31, Given these uncertainties, you are advised not to place any undue reliance on such forward-looking statements. All statements contained herein speak only as of the release date of this document. Galapagos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation. Under no circumstances may any copy of this presentation, if obtained, be retained, copied or transmitted. 2
3 GLPG: strong investment case Candidates for $80+B inflammation & fibrosis markets Proven platform for innovation, deep pipeline Late stage data from every major program in 2020 Building commercial infrastructure Strong cash position for growth with ~$1.4 B 3
4 GLPG: data rich 2018 Filgotinib Best-in-class JAK Topline results in 3 indications (RA, PsA, AS) Building commercial organization with Gilead IPF Start 1690 late stage studies in H1 18 Franchise of 3 proprietary novel assets CF Individual components validated in patients Topline 1 st triple in patients mid 18 Expanding pipeline 19 Ph2 trials in 18 Additional novel drugs into clinic 4
5 Advancing our innovation to market Potential for multiple product launches New pipeline opportunities Pivotal trials Expansion of late stage pipeline Commercial preparations GILD partnership 2nd and 3rd PoC on novel targets 5
6 Strong R&D Area Preclinical Ph1 Ph2 Ph3 Filgotinib 10+ indications evaluated in Ph2 and Ph3, pivotal trial completion as of 2018 IPF Multiple late stage trials to start in H1 18, fully proprietary CF Ph2 to start Q1 18 Atopic dermatitis OA Inflammation Fibrosis Ph2 to start H1 18 >20 programs 6
7 Unique target discovery engine NOVEL TARGETS disease-modifying multiple disease areas first-in-class candidates SMART DEVELOPMENT rapid, multiple PoCs swift moves to pivotal development 3 PROOF OF CONCEPTS filgotinib (JAK1) 1690 (autotaxin) MOR106 (IL17-C) 7
8 Partnerships Gilead: filgotinib $750M upfront $1.35B in milestone payments profit-split, co-promote in 8 EU countries 20-30% royalties AbbVie: CF $600M milestones profit-split and co-promotion in Benelux China/Korea rights 15-20% royalties Servier: 1972 $290M milestones single digit % royalties US rights MorphoSys: MOR106 50/50 cost/benefit 8
9 Building an IPF franchise Drug (MoA) Pre-clinical Ph 1 Ph 2 Ph 3 '1690 (Autotaxin) '1205 (GPR84) '3499 Status Jan 18 Expected progress in 2018 Fully proprietary, oral therapies Three novel modes of action to address unmet need Opportunity to investigate combinations 1690 has orphan drug designation in EU & US GLPG to commercialize IPF assets 9
10 IPF: $5B market by 2025 Large unmet need remains About IPF Progressive lung scarring leading to death Median survival 2-5 years Mostly male patients, >50 years Diagnosis via HRCT or biopsy 200,000 cases in US & EU 2016 drug sales $1.2B EU 21% Japan 5% Ofev & Esbriet have limitations Only slow FVC decline ~25% annual discontinuations List price ~$95,000/yr US 74% Sources: Stifel, Global Data Note: Ofev is a drug marketed by Boehringer Ingelheim, Esbriet is a drug marketed by Roche 10
11 Positive 1690 data in patients Flora Placebo mg *= p<0.05 Placebo 1690 BSL N=6 N=17 4 N=3 N=16 8 N=4 N=15 12 N=4 N=13 FU N=4 N=15 FVC stabilization over 12-week period 11
12 FRI shows disease stabilization Flora Functional respiratory imaging tracks ahead of FVC 12
13 Strong biomarker reduction Flora Reduction of LPA18:2 in blood plasma Placebo mg Placebo 1690 BSL N=6 N=17 4 N=5 N=16 12 N=6 N=15 FU N=5 N=15 **= p<0.01 Biomarker reduction = target engagement 13
14 5 4 Ashcroft score (median) Score (median) Ashcroft score Volume (ml) Additional novel mechanisms in IPF 3499: target undisclosed BLM signs & symptoms * * 1205: targets GPR84 BLM inspiratory capacity Healthy BLM (30mg/kg bid) BLM - Ofev (60mg/kg qd) BLM - Diseased Healthy *=p>0.05 PBS + vehicle Diseased BLM + vehicle Ofev 60mg/kg qd BLM + Ninte QD, 60mpk mg/kg bid BLM+G Pressure (cm H 2 0) 3499 and 1205 reduce IPF signs & symptoms in BLM model Note: both experiments are 21 day therapeutic bleomycin lung fibrosis model in mice (BLM) 14
15 Building the filgotinib franchise Area Ph 1 Ph 2 Ph 3 RA Crohn s disease Ulcerative colitis Ankylosing spondylitis Psoriatic arthritis Small bowel CD Fistulizing CD Sjögren s Cutaneous lupus Lupus nephropathy Uveitis Status Jan 18 Expected progress in
16 Filgotinib Potential to redefine treatment standards in RA & IBD SAFE EFFICACIOUS CONVENIENT most selective JAK1 >2000 PYE best biomarker & AE profile so far strong in RA unprecedented in CD in biologic naive rapid onset and sustained response once-daily oral monotherapy Note: potential indicated here is based on Ph2 filgotinib data, no head to head comparison studies, flgotinib is an investigational candidate drug 16
17 Inflammation market ~$65B by 2027 Market growth drivers ~2027 market size, $B Current use of biologics <40% Oral and monotherapy Rapid response Higher, maintained efficacy AS ~8 UC ~9 PsA ~10 CD ~10 RA ~30 Source: Goldman Sachs 2017, Leerink 2017, Stifel 2017, Global Data, Galapagos estimates 17
18 Fold selectivity Filgotinib Most JAK1 selective JAK1 vs. JAK2 JAK1 vs. JAK filgotinib tofacitinib baricitinib upadacitinib 00 filgotinib tofacitinib baricitinib upadacitinib Source: Galapagos human whole blood assay Source: Galapagos biochemical assay Independently confirmed at ACR 2017* * Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations, McInnes et al, ACR
19 Superior efficacy JAK class in RA ACR50% ACR50% (W12, (W12) active delta) placebo active active delta mg QD + MTX 100 mg Q.D. + MTX (DARWIN-1, 2016, W12) 200 mg QD + MTX 200 mg Q.D. + MTX (DARWIN-1, 2016, W12) 40mg EOW + cdmards Adalimumab 40mg EOW (RA-BEAM, 2017, W12) 2 mg QD + cdmards 2 mg Q.D. + cdmards (RA-BUILD, 2017, W12) 4 mg Q.D. + cdmards (RA-BUILD, 2017, W12) 15 mg Q.D. + cdmards (SELECT NEXT, 2017, + cdmards W12) Filgotinib Baricitinib Upadacitinib Filgotinib DARWIN 1 Humira MTX IR (cdmard IR) Baricitinib 4 mg QD + cdmards 15 mg QD Upadacitinib RA-BEAM RA-BUILD SELECT-NEXT 30 mg QD 30 mg Q.D. + cdmards (SELECT NEXT, 2017, + cdmards W12) Note: data not from head-to-head studies 19
20 Superior efficacy in CD, TNF naive Clinical remission: induction Active delta to placebo, % responders Filgotinib 200mg W10 FITZROY Humira 160mg W4 CLASSIC-1 Xeljanz 5mg W8 Panes et al 2017 Cimzia 400mg W12 PRECISE-1 Stelara 6mg/kg IV W10 Entyvio 300mg W10 GEMINI-3 Note: data not from head-to-head studies 20
21 Beneficial hemoglobin profile EPO-JAK2 selectivity Hb mean CFB (g/dl), W pbo 100mg200mg qd qd pbo 2mg qd 4mg qd pbo 5mg bid 10mg bid pbo 6mg bid 12mg bid 18mg bid filgotinib baricitinib tofacitinib upadacitinib Note: data from separate RA studies not conducted by the Company. filgotinib Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib Dougados et al, Annrheumdis 2016, 21 RA-BUILD; tofacitinib FDA AdComm briefing document May 2012; upadacitinib Genovese et al A&R 2016 BALANCE 2.
22 No reduction of NK cells NK cells, mean CFB (%), W pbo 100mg200mg qd qd pbo 2mg qd 4mg qd pbo 5mg bid 15mg bid pbo 6mg bid 12mg bid 18mg bid filgotinib baricitinib* tofacitinib** upadacitinib Note: data from separate RA studies not conducted by the Company. filgotinib Westhovens et al, and Kavanaugh et al, ARD 2016; baricitinib Dougados et al, Annrheumdis 2016, RA-BUILD and Tanaka EULAR 2016 abstract RA-BEAM; tofacitinib Van Vollenhoven abstract 2013, median CFB at W6; upadacitinib Genovese et al A&R 2016 BALANCE 2. 22
23 Change from baseline (10 9 /L) Reduction of platelets platelets, mean CFB (giga/l), W pbo 100mg qd 200mg qd pbo 2mg qd 4mg qd pbo 5mg bid 10mg bid pbo 6mg bid 12mg bid 18mg bid filgotinib baricitinib tofacitinib upadacitinib Note: filgotinib DARWIN 1 W12 results; baricitinib Dougados et al, Annrheumdis 2016; tofacitinib FDA AdComm briefing document May 2012, upadacitinib Genovese et al ACR
24 Low incidence DVT and infections Event Per 100 PYE filgotinib (50-)200mg daily DARWIN 3 Wk 84 upadacitinib 6 and 12mg BID baricitinib 2 and 4mg QD tofacitinib 5mg bid tocilizumab 4 and 8 mg/kg adalimumab Genovese, ACR2017 Genovese et al., ACR2017 Genovese et al, ACR 2017 Wollenhaupt et al, ACR 2017 Genovese et al, ACR 2012 Burmester et al, 2011 Patient year exposure 1, ,637 5,891 14,994 23,943 Serious infection Herpes Zoster NR NR DVT/PEs N cases/100py 2/1, / /6, /1,849* * DVT/PE data on tofacitinib from Mease et al, ACR2017, 5mg bid 24
25 CF portfolio 4 patient studies in Q 2Q 3Q 4Q PELICAN Interim readout FALCON (1st triple) Europe 2nd triple US + Europe 3rd triple 25
26 CF approach to triple combo today Discover novel correctors & potentiators Validate triple combo in patients Validate individual components in patients: Potentiator: SAPHIRA C1: ALBATROSS, FLAMINGO C2: PELICAN ( ) Comprehensive clinical network Multiple triples in patient studies >130 patients, 10 countries, >60 sites in studies to date Interim results of 1 st triple therapy in patients expected mid 18 26
27 ALBATROSS 4 wks up to 2 wks 2222, oral, 300 mg once daily (n=14) Screening 2222, oral, 150 mg once daily (n=14) Placebo (n=7) Ivacaftor 150 mg twice daily Follow-up Adult CF patients Class III/Class II, on stable ivacaftor treatment 37 patients enrolled in Europe and Australia 27
28 Clear activity profile D29 vs. baseline Sweat chloride Absolute ppfev 1 changes mmol/l %ppfev Placebo 150 mg 300 mg 0 Placebo 150 mg mg * * -5 * (p<0.05) 28
29 Cohort B Cohort A FLAMINGO 2222 in homozygous F508del patients 4 wks up to 2 wks 2222, oral, dose 1 or 2 once daily (n=20) Screening Placebo (n=5) 2222, oral, dose 3 or 4 once daily (n=20) Followup Placebo (n=5) Comparable to study of VX-661 In F508del homozygous Donaldson 2017 Adult CF patients homozygous F508del mutation 59 patients enrolled in two sequential cohorts (A & B) 4 doses GLPG2222 QD 24 sites: US, UK, Belgium, Netherlands, Serbia, Spain 29
30 On target activity Mean changes D29 vs. baseline Sweat chloride Absolute ppfev 1 changes mmol/l %ppfev 1 Pbo Dose 1 Dose 2 Dose 3 Dose 4 Pbo Dose 1 Dose 2 Dose 3 Dose * (p<0.05) * LOCF values Mean ±SE Dose dependent decrease in SwCl, demonstrating CFTR on target activity
31 PELICAN 2737 in Orkambi-treated F508del/F508del patients 4 wks up to 3 wks Screening 2737, 150 mg daily, oral (n=12) Placebo (n=6) Follow-up Orkambi (400 mg lumacaftor, 250 mg ivacaftor twice daily) Adult CF patients homozygous for F508del mutation Patients remain on stable dose of Orkambi 31
32 1972 for osteoarthritis OA: breakdown of joint cartilage 118 M patients in US, Europe & Japan No disease-modifying drugs approved today Targets ADAMTS-5 Inhibits cartilage breakdown biomarker in healthy volunteers Phase 1: clear target engagement, favorable safety & PK GLPG Ph1b 30-patient study in US: positive data Ph2 start in US planned in H
33 Strong reduction of ARGS 1972 Ph1b study in OA patients -20 ARGS % reduction vs baseline Blood serum ARGS % reduction vs baseline placebo Placebo 1972 Low dose Med dose High dose Days post-dosing Dose-dependent reduction of ARGS, well-tolerated in OA patients 33
34 MOR106 for atopic dermatitis AtopicD: disease causing very dry skin, severe itching 35M patients in US, Europe & Japan First-in-class human MAb Novel MOA: IL-17C target discovered by Galapagos Ph1 (SAD): favorable safety & PK in healthy volunteers Ph1b (MAD): 83% patients at EASI50 within 4 weeks at highest dose Ph2 start in H
35 2018 late-stage clinical newsflow TRIAL INITIATIONS Late stage 1690 in IPF Ph in IPF CF FALCON Ph2 2 nd CF triple combo Ph2 3 rd CF triple combo Ph in OA in US Ph2 MOR106 in AtD POC DATA Filgo in PsoA (EQUATOR) Filgo in AS (TORTUGA) CF PELICAN CF FALCON PIVOTAL DATA Filgo in RA (FINCH 2) Filgo interim UC (SELECTION, go/no go) 35
36 glpg.com
Novel targets, better treatments
Novel targets, better treatments Investor presentation March 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of
More informationNovel targets, better treatments
Novel targets, better treatments Investor presentation May 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our
More informationNovel targets, better treatments
Novel targets, better treatments Investor presentation Sept 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our
More informationNovel targets, better treatments
Novel targets, better treatments Investor presentation November 2016 Copyright 2016 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely
More informationQ1 Results 2018 Webcast presentation 26 April 2018
Q1 Results 2018 Webcast presentation 26 April 2018 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our clinical pipeline,
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationNovel targets, better treatments
Novel targets, better treatments Investor Presentation Nov 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our
More informationNovel targets, better treatments
Novel targets, better treatments Investor Presentation Oct 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the progress of our
More informationGLPG1690 FLORA topline results
GLPG1690 FLORA topline results Webcast presentation 10 August 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the potential activity
More informationJefferies Healthcare Conference. June 6, 2018
Jefferies Healthcare Conference June 6, 2018 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationBTIG LLC Dane Leone, CFA (212) Source: SAPHIRA 1 Results (December 20th 2016), Ph2a open label trial of GLPG1837
Pre-clinical assay outcomes at Vertex have proven to be reliable markers for in vivo results, we expect the same from Galapagos: Outcomes from the EVOLVE and EXPAND studies have set a new bar for clinical
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More informationJefferies Healthcare Conference June 8, 2017
Jefferies Healthcare Conference June 8, 2017 1 Forward-Looking Statements and Non-GAAP Financial Information Some statements in this presentation may be forward-looking statements for purposes of the Private
More informationProthena Corporation plc
Prothena Corporation plc PRX003 Investor Update: Phase 2 Development Strategy September 29, 2016 Agenda Dr. Gene Kinney, Chief Operating Officer Introduction Dr. Ken Flanagan, Senior Scientist Th17 and
More informationPhase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients
Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients July 18, 2017 Agenda Introduction Michael Partridge, VP Investor Relations
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationPhase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures
Phase 3 EVOLVE & EXPAND Studies of Tezacaftor/Ivacaftor Combination Show Statistically Significant Improvements in Lung Function and Other Measures in CF Patients March 29, 2017 Agenda Introduction Michael
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationJefferies Healthcare Conference. June 25, 2008
Jefferies Healthcare Conference June 25, 2008 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationREFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Xeljanz (tofacitinib) in the 10MM
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationCAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationJP Morgan Healthcare Conference. January 8, 2007
JP Morgan Healthcare Conference January 8, 2007 Safe Harbor Statement Except for the historical information set forth herein, the matters set forth in this presentation,including without limitation statements
More informationREFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Cimzia (certolizumab pegol)
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBank of America Merrill Lynch 2016 Health Care Conference
Bank of America Merrill Lynch 2016 Health Care Conference Dr. Steven Stein Chief Medical Officer David Gryska Chief Financial Officer May 11, 2016 Forward Looking Statements Except for the historical information
More informationAmerican College of Rheumatology Analyst and Investor Meeting November 6, 2011
American College of Rheumatology 2011 Analyst and Investor Meeting November 6, 2011 Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements Our discussions during this meeting
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationREFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Mavrilimumab in the 10MM Rheumatoid Arthritis
More informationREFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Iguratimod/T-614 in the 10MM (US, France,
More informationACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC498DFR PUBLICATION DATE DECEM BER 2014 ACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Actemra/RoActemra (tocilizumab)
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationREFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Sarilumab in the 10MM Rheumatoid Arthritis (RA)
More informationREFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Orencia (abatacept) in the 10MM (US,
More informationCavosonstat Phase 2 Trial Results. November 28 th, 2016
Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCreating a Leading Global HBV Therapeutics Company. ARB-1467 Update Call December 12, 2016
Creating a Leading Global HBV Therapeutics Company ARB-1467 Update Call December 12, 2016 NASDAQ: ABUS www.arbutusbio.com Forward Looking Statements This presentation contains forward-looking statements
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationProthena Corporation plc Overview
November 11, 2014 Prothena Corporation plc Overview 2014 Credit Suisse HC Conference The Arizona Biltmore Phoenix, AZ Forward-Looking Statements This presentation contains forward-looking statements. These
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationi-bodies a new class of protein therapeutics to treat fibrosis
i-bodies a new class of protein therapeutics to treat fibrosis BIOSHARES JULY 2017 Sam Cobb, CEO and Managing Director AdAlta Limited (ASX:1AD) s.cobb@adalta.com.au Disclaimer Investment in AdAlta is subject
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationSER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017
SER-287 Phase 1b topline study results in patients with mild-to-moderate Ulcerative Colitis October 2, 2017 Leading the Microbiome Revolution Forward Looking Statements Some of the statements in this presentation
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationTheravance Biopharma, Inc. (NASDAQ: TBPH)
Theravance Biopharma, Inc. (NASDAQ: TBPH) FDA Approval of YUPELRI TM (revefenacin) Inhalation Solution November 9, 2018 THERAVANCE and the Cross/Star logo are registered trademarks of the Theravance Biopharma
More informationBreathtaking science. Developing respiratory drugs to improve health and quality of life. H.C. Wainwright Global Life Sciences Conference April 2018
Breathtaking science Developing respiratory drugs to improve health and quality of life H.C. Wainwright Global Life Sciences Conference April 2018 www.veronapharma.com Forward-Looking Statements This presentation
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationSAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines
SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines Presented by Dan Browne, Co-Founder, President & CEO, and
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationUtrophin Modulation: A Universal Treatment Approach to DMD. End Duchenne Tour April 2018
Utrophin Modulation: A Universal Treatment Approach to DMD April 2018 Legal Disclaimer Statements in this presentation, other than statements of historical fact, constitute forward-looking statements within
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationUBS Global Healthcare Conference May 19, 2014
UBS Global Healthcare Conference May 19, 2014 Safe Harbor Statement This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationCompany Overview. Dr. Neal Walker President and CEO. September Copyright 2016 Aclaris Therapeutics. All rights reserved.
Company Overview Dr. Neal Walker President and CEO Copyright 2016 Aclaris Therapeutics. All rights reserved. A-11 Disclaimer This presentation contains forward-looking statements, including statements
More informationAquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC. August 6, 2015
Aquinox Q2 /2015 Conference Call: LEADERSHIP Secondary Endpoint Update - AQX-1125 in BPS/IC August 6, 2015 Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationNew SEL-212 Phase 2 Data Presented at EULAR. June 15, 2018
New SEL-1 Phase Data Presented at EULAR June 15, 1 Safe Harbor / Disclaimer Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. ( the company
More informationTargeted Therapeutics for Inflammatory Disease
Targeted Therapeutics for Inflammatory Disease Forward Looking Statements / Safe Harbor This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationSeladelpar Interim Data Phase 2 Low Dose Study in PBC. July 17, 2017
Seladelpar Interim Data Phase 2 Low Dose Study in PBC July 17, 2017 Seladelpar Phase 2 Low Dose Study in PBC Potential for superior efficacy and better tolerability 39% (5 mg) and 45% (10 mg) reductions
More information